Action APLS APELLIS PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Apellis Pharmaceuticals, Inc.

Actions

APLS

US03753U1060

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 02/05/2024 		Varia. 5j. Varia. 1 janv.
47,49 USD +3,13% Graphique intraday de Apellis Pharmaceuticals, Inc. -0,92% -20,66%
29/04 APELLIS PHARMACEUTICALS, INC. : Mizuho Securities toujours neutre sur le dossier ZM
26/04 Apellis Pharmaceuticals déclare que l'EMA déplace la demande de pegcetacoplan à la dernière phase de l'évaluation initiale MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing
Apellis Pharmaceuticals Insider Sold Shares Worth $645,838, According to a Recent SEC Filing
Apellis Pharmaceuticals Insider Sold Shares Worth $4,297,549, According to a Recent SEC Filing
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024
Apellis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Pharmaceuticals Insider Sold Shares Worth $16,028,706, According to a Recent SEC Filing
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer
Apellis Pharmaceuticals' Q4 Net Loss Narrows, Revenue Increases
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action APLS
  4. Actualités Apellis Pharmaceuticals, Inc.
  5. Autres langues